Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Cardiology Reports
Erschienen in: Current Cardiology Reports 2/2014

01.02.2014 | Diabetes and Cardiovascular Disease (S Malik, Section Editor)

Role of Cardiac MRI in Diabetes

verfasst von: Ravi V. Shah, Siddique A. Abbasi, Raymond Y. Kwong

Erschienen in: Current Cardiology Reports | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Diabetes and insulin resistance have a variety of detrimental effects on cardiovascular health and outcomes. Cardiac magnetic resonance offers a non-invasive means to obtain many layers of information at a tissue level, including fibrosis, edema, intramyocardial motion, triglyceride content, and myocardial energetics. The role of cardiovascular magnetic resonance is particularly important in the evaluation of recognized and unrecognized coronary artery disease. In this review, we address the current state-of-the-art in cardiac magnetic resonance imaging – for both clinical and investigational use – as it applies to diabetic cardiovascular disease.
Literatur
1.
Kannel W, Hjortland M, Castelli W. Role of diabetes in congestive heart failure: the Framingham Study. Am J Cardiol. 1976;34:29–34.CrossRef
2.
de Simone G, Devereux RB, Chinali M, et al. Diabetes and incident heart failure in hypertensive and normotensive participants of the Strong Heart Study. J Hypertens. 2010;28:353–60.PubMedCentralPubMedCrossRef
3.
Burchfiel C, Reed D, Marcus E, Strong J, Hayashi T. Association of diabetes mellitus with coronary atherosclerosis and myocardial lesions: an autopsy study from the Honolulu Heart Program. Am J Epidemiol. 1993;137:1328–40.PubMed
4.
Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev. 2004;25:543–67.PubMedCrossRef
5.
American College of Cardiology Foundation Task Force on Expert Consensus D, Hundley WG, Bluemke DA, et al. ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol. 2010;55:2614–62.PubMedCrossRef
6.
Al-Saadi N, Nagel E, Gross M, et al. Noninvasive detection of myocardial ischemia from perfusion reserve based on cardiovascular magnetic resonance. Circulation. 2000;101:1379–83.PubMedCrossRef
7.
Raman SV, Simonetti OP, Winner 3rd MW, et al. Cardiac magnetic resonance with edema imaging identifies myocardium at risk and predicts worse outcome in patients with non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol. 2010;55:2480–8.PubMedCentralPubMedCrossRef
8.
Assomull RG, Prasad SK, Lyne J, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol. 2006;48:1977–85.PubMedCrossRef
9.
Hudsmith LE, Tyler DJ, Emmanuel Y, et al. 31P cardiac magnetic resonance spectroscopy during leg exercise at 3 Tesla. Int J Cardiovasc Imaging. 2009;25:819–26.PubMedCrossRef
10.
Ng AC, Delgado V, Bertini M, et al. Myocardial steatosis and biventricular strain and strain rate imaging in patients with type 2 diabetes mellitus. Circulation. 2010;122:2538–44.PubMedCrossRef
11.
Rosen BD, Saad MF, Shea S, et al. Hypertension and smoking are associated with reduced regional left ventricular function in asymptomatic: individuals the Multi-Ethnic Study of Atherosclerosis. J Am Coll Cardiol. 2006;47:1150–8.PubMedCrossRef
12.
Paetsch I, Jahnke C, Wahl A, et al. Comparison of dobutamine stress magnetic resonance, adenosine stress magnetic resonance, and adenosine stress magnetic resonance perfusion. Circulation. 2004;110:835–42.PubMedCrossRef
13.
Gebker R, Jahnke C, Paetsch I, et al. MR myocardial perfusion imaging with k-space and time broad-use linear acquisition speed-up technique: feasibility study. Radiology. 2007;245:863–71.PubMedCrossRef
14.
Amado LC, Gerber BL, Gupta SN, et al. Accurate and objective infarct sizing by contrast-enhanced magnetic resonance imaging in a canine myocardial infarction model. J Am Coll Cardiol. 2004;44:2383–9.PubMedCrossRef
15.
Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;100:1992–2002.PubMedCrossRef
16.
Flett AS, Hasleton J, Cook C, et al. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. JACC Cardiovasc Imaging. 2011;4:150–6.PubMedCrossRef
17.
Schwitter J, Nanz D, Kneifel S, et al. Assessment of myocardial perfusion in coronary artery disease by magnetic resonance: a comparison with positron emission tomography and coronary angiography. Circulation. 2001;103:2230–5.PubMedCrossRef
18.
Peters DC, Appelbaum EA, Nezafat R, et al. Left ventricular infarct size, peri-infarct zone, and papillary scar measurements: a comparison of high-resolution 3D and conventional 2D late gadolinium enhancement cardiac MR. J Magn Reson Imaging. 2009;30:794–800.PubMedCentralPubMedCrossRef
19.
•• Ng AC, Auger D, Delgado V, et al. Association between diffuse myocardial fibrosis by cardiac magnetic resonance contrast-enhanced T (1) mapping and subclinical myocardial dysfunction in diabetic patients: a pilot study. Circ Cardiovasc Imaging. 2012;5:51–9. This manuscript was one of the first demonstrations that diffuse myocardial fibrosis as assessed by T1 mapping CMR techniques is associated with diastolic dysfunction and strain in diabetes.PubMedCrossRef
20.
Rijzewijk LJ, van der Meer RW, Lamb HJ, et al. Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol. 2009;54:1524–32.
21.
Rijzewijk LJ, van der Meer RW, Smit JW, et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol. 2008;52:1793–9.
22.
Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971–1993. Diabetes Care. 1998;21:1138–45.PubMedCrossRef
23.
Eberly LE, Cohen JD, Prineas R, Yang L. Intervention Trial Research g. Impact of incident diabetes and incident nonfatal cardiovascular disease on 18-year mortality: the multiple risk factor intervention trial experience. Diabetes Care. 2003;26:848–54.PubMedCrossRef
24.
Abbott RD, Donahue RP, Kannel WB, Wilson PW. The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham Study. JAMA. 1988;260:3456–60.PubMedCrossRef
25.
Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–34.PubMedCrossRef
26.
Wu KC, Weiss RG, Thiemann DR, et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol. 2008;51:2414–21.PubMedCentralPubMedCrossRef
27.
Wu E, Ortiz JT, Tejedor P, et al. Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: prospective cohort study. Heart. 2008;94:730–6.PubMedCrossRef
28.
Kwong RY, Sattar H, Wu H, et al. Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. Circulation. 2008;118:1011–20.
29.
•• Schelbert EB, Cao JJ, Sigurdsson S, et al. Prevalence and prognosis of unrecognized myocardial infarction determined by cardiac magnetic resonance in older adults. JAMA. 2012;308:890–6. This is one of the largest prospective, community based studies demonstrating the prognostic importance of LGE CMR; these authors specifically comment on the prognostic utility of LGE CMR in diabetics.PubMedCrossRef
30.
• Turkbey EB, Backlund JY, Genuth S, et al. Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. Circulation. 2011;124:1737–46. This study from the DCCT trial demonstrates a relationship between glycemic control and aberrant LV structure and function.PubMedCentralPubMedCrossRef
31.
• Yoon YE, Kitagawa K, Kato S, et al. Prognostic significance of unrecognized myocardial infarction detected with MR imaging in patients with impaired fasting glucose compared with those with diabetes. Radiology. 2012;262:807–15. This study extends the results of Kwong et al. (reference 29) to patients with pre-diabetes (impaired fasting glucose), with similar results that LGE CMR is prognostic even before the onset of type 2 diabetes.PubMedCrossRef
32.
Mather AN, Crean A, Abidin N, et al. Relationship of dysglycemia to acute myocardial infarct size and cardiovascular outcome as determined by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2010;12:61.PubMedCrossRef
33.
Jensen CJ, Eberle HC, Nassenstein K, et al. Impact of hyperglycemia at admission in patients with acute ST-segment elevation myocardial infarction as assessed by contrast-enhanced MRI. Clin Res Cardiol. 2011;100:649–59.PubMedCrossRef
34.
Gottumukkala RV, Lv H, Cornivelli L, Wagers AJ, Kwong RY, Bronson R, et al. Myocardial infarction triggers chronic cardiac autoimmunity in type 1 diabetes. Sci Transl Med 2012;4:138ra180.
35.
Young LH, Wackers FJ, Chyun DA, et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA. 2009;301:1547–55.PubMedCentralPubMedCrossRef
36.
Shaw LJ, Cerqueira MD, Brooks MM, et al. Impact of left ventricular function and the extent of ischemia and scar by stress myocardial perfusion imaging on prognosis and therapeutic risk reduction in diabetic patients with coronary artery disease: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. J Nucl Cardiol Off Publ Am Soc Nucl Cardiol. 2012;19:658–69.CrossRef
37.
Nandalur KR, Dwamena BA, Choudhri AF, Nandalur MR, Carlos RC. Diagnostic performance of stress cardiac magnetic resonance imaging in the detection of coronary artery disease: a meta-analysis. J Am Coll Cardiol. 2007;50:1343–53.PubMedCrossRef
38.
Schwitter J, Wacker CM, van Rossum AC, et al. MR-IMPACT: comparison of perfusion-cardiac magnetic resonance with single-photon emission computed tomography for the detection of coronary artery disease in a multicentre, multivendor, randomized trial. Eur Heart J. 2008;29:480–9.PubMedCrossRef
39.
Greenwood JP, Maredia N, Younger JF, et al. Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial. Lancet. 2012;379:453–60.PubMedCentralPubMedCrossRef
40.
Jahnke C, Nagel E, Gebker R, et al. Prognostic value of cardiac magnetic resonance stress tests: adenosine stress perfusion and dobutamine stress wall motion imaging. Circulation. 2007;115:1769–76.PubMedCrossRef
41.
Buckert D, Dewes P, Walcher T, Rottbauer W, Bernhardt P. Intermediate-term prognostic value of reversible perfusion deficit diagnosed by adenosine CMR: a prospective follow-up study in a consecutive patient population. JACC Cardiovasc Imaging. 2013;6:56–63.PubMedCrossRef
42.
Korosoglou G, Elhmidi Y, Steen H, et al. Prognostic value of high-dose dobutamine stress magnetic resonance imaging in 1,493 consecutive patients: assessment of myocardial wall motion and perfusion. J Am Coll Cardiol. 2010;56:1225–34.PubMedCrossRef
43.
Bingham SE, Hachamovitch R. Incremental prognostic significance of combined cardiac magnetic resonance imaging, adenosine stress perfusion, delayed enhancement, and left ventricular function over preimaging information for the prediction of adverse events. Circulation. 2011;123:1509–18.PubMedCrossRef
44.
Steel K, Broderick R, Gandla V, et al. Complementary prognostic values of stress myocardial perfusion and late gadolinium enhancement imaging by cardiac magnetic resonance in patients with known or suspected coronary artery disease. Circulation. 2009;120:1390–400.PubMedCentralPubMedCrossRef
45.
Fihn SD, Gardin JM, Abrams J, et al. ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60:e44–e164.PubMedCrossRef
46.
Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care. 2004;27:1879–84.PubMedCrossRef
47.
Heckbert SR, Post W, Pearson GD, et al. Traditional cardiovascular risk factors in relation to left ventricular mass, volume, and systolic function by cardiac magnetic resonance imaging: the Multiethnic Study of Atherosclerosis. J Am Coll Cardiol. 2006;48:2285–92.PubMedCentralPubMedCrossRef
48.
Bertoni AG, Goff Jr DC, D'Agostino Jr RB, et al. Diabetic cardiomyopathy and subclinical cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care. 2006;29:588–94.
49.
Wang L, Jerosch-Herold M, Jacobs Jr DR, Shahar E, Folsom AR. Coronary risk factors and myocardial perfusion in asymptomatic adults: the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol. 2006;47:565–72.PubMedCrossRef
50.
Velagaleti RS, Gona P, Chuang ML, et al. Relations of insulin resistance and glycemic abnormalities to cardiovascular magnetic resonance measures of cardiac structure and function: the Framingham Heart Study. Circ Cardiovasc Imaging. 2010;3:257–63.PubMedCentralPubMedCrossRef
51.
Shah RV, Abbasi SA, Heydari B, et al. Insulin resistance, subclinical left ventricular remodeling, and the obesity paradox: the multi-ethnic study of atherosclerosis. J Am Coll Cardiol. 2013.
52.
Hudsmith LE, Neubauer S. Magnetic resonance spectroscopy in myocardial disease. JACC Cardiovasc Imaging. 2009;2:87–96.
53.
Hammer S, Snel M, Lamb HJ, et al. Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function. J Am Coll Cardiol. 2008;52:1006–12.PubMedCrossRef
54.
Zib I, Jacob AN, Lingvay I, et al. Effect of pioglitazone therapy on myocardial and hepatic steatosis in insulin-treated patients with type 2 diabetes. J Investig Med. 2007;55:230–6.PubMedCrossRef
55.
Korosoglou G, Humpert PM, Ahrens J, et al. Left ventricular diastolic function in type 2 diabetes mellitus is associated with myocardial triglyceride content but not with impaired myocardial perfusion reserve. J Magn Reson Imaging. 2012;35:804–11.PubMedCrossRef
56.
van der Meer RW, Rijzewijk LJ, de Jong HW, et al. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation. 2009;119:2069–77.
57.
• McGavock J, Szczepaniak LS, Ayers CR, et al. The effects of rosiglitazone on myocardial triglyceride content in patients with type 2 diabetes: a randomised, placebo-controlled trial. Diab Vasc Dis Res. 2012;9:131–7. A study of the therapeutic effects of glitazone therapy on myocardial steatosis and energetics in diabetes. This represents a use of CMR in tracking therapeutic responses in patients with diabetes.PubMedCrossRef
58.
McGavock JM, Lingvay I, Zib I, et al. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation. 2007;116:1170–5.
59.
Scheuermann-Freestone M, Madsen PL, Manners D, et al. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation. 2003;107:3040–6.PubMedCrossRef
60.
Diamant M, Lamb HJ, Groeneveld Y, et al. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol. 2003;42:328–35.PubMedCrossRef
61.
Rijzewijk LJ, Jonker JT, van der Meer RW, et al. Effects of hepatic triglyceride content on myocardial metabolism in type 2 diabetes. J Am Coll Cardiol. 2010;56:225–33.PubMedCrossRef
62.
Shivu GN, Phan TT, Abozguia K, et al. Relationship between coronary microvascular dysfunction and cardiac energetics impairment in type 1 diabetes mellitus. Circulation. 2010;121:1209–15.PubMedCrossRef
63.
Metzler B, Schocke MF, Steinboeck P, et al. Decreased high-energy phosphate ratios in the myocardium of men with diabetes mellitus type I. J Cardiovasc Magn Reson. 2002;4:493–502.PubMedCrossRef
64.
65.
Das A, Das J, Chandrasekar S. Specific heart muscle disease in diabetes mellitus - a functional structural correlation. Int J Cardiol. 1987;17:299–302.PubMedCrossRef
66.
67.
Nunoda S, Genda A, Sugihara N, Nakayama A, Mizuno S, Takeda R. Quantitative approach to the histopathology of the biopsied right ventricular myocardium in patients with diabetes mellitus. Heart Vessel. 1985;1:43–7.CrossRef
68.
Messroghli DR, Radjenovic A, Kozerke S, Higgins DM, Sivananthan MU, Ridgway JP. Modified Look-Locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart. Magn Reson Med Off J Soc Magn Reson Med Soc Magn Reson Med. 2004;52:141–6.CrossRef
69.
Piechnik SK, Ferreira VM, Dall'Armellina E, et al. Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold. J Cardiovasc Magn Reson. 2010;12:69.PubMedCrossRef
70.
Coelho-Filho OR, Mongeon FP, Mitchell R, et al. Role of transcytolemmal water-exchange in magnetic resonance measurements of diffuse myocardial fibrosis in hypertensive heart disease. Circ Cardiovasc Imaging. 2013;6:134–41.PubMedCentralPubMedCrossRef
71.
Flett AS, Sado DM, Quarta G, et al. Diffuse myocardial fibrosis in severe aortic stenosis: an equilibrium contrast cardiovascular magnetic resonance study. Eur Heart J Cardiovasc Imaging. 2012;13:819–26.PubMedCrossRef
72.
•• Wong TC, Piehler K, Meier CG, et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation. 2012;126:1206–16. A landmark study demonstating the value of T1 mapping to forecast mortality in an adult population.PubMedCentralPubMedCrossRef
73.
•• Jellis C, Wright J, Kennedy D, et al. Association of imaging markers of myocardial fibrosis with metabolic and functional disturbances in early diabetic cardiomyopathy. Circ Cardiovasc Imaging. 2011;4:693–702. One of the first studies exmaining the relationship between myocardial fibrosis by T1 mapping and metabolism (e.g., insulin resistance) and cardiac function in diabetes.PubMedCrossRef
74.
Giannetta E, Isidori AM, Galea N, et al. Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. Circulation. 2012;125:2323–33.PubMedCrossRef
75.
Rao AD, Shah RV, Garg R, et al. Aldosterone and myocardial extracellular matrix expansion in type 2 diabetes mellitus. Am J Cardiol. 2013;112(1):73–8.PubMedCrossRef
76.
Ho CY, Abbasi SA, Neilan TG, et al. T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. Circ Cardiovasc Imaging. 2013;6:415–22.PubMedCrossRef
Metadaten
Titel
Role of Cardiac MRI in Diabetes
verfasst von
Ravi V. Shah
Siddique A. Abbasi
Raymond Y. Kwong
Publikationsdatum
01.02.2014
Verlag
Springer US
Erschienen in
Current Cardiology Reports / Ausgabe 2/2014
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-013-0449-0

Weitere Artikel der Ausgabe 2/2014

Current Cardiology Reports 2/2014 Zur Ausgabe

Diabetes and Cardiovascular Disease (S Malik, Section Editor)

The Obesity Paradox in Diabetes

Ischemic Heart Disease (D Mukherjee, Section Editor)

Long-Term Clinical Outcomes after Percutaneous Coronary Intervention for Chronic Total Occlusions

Diabetes and Cardiovascular Disease (S Malik, Section Editor)

Role of Bariatric Surgery in Diabetes

Ischemic Heart Disease (D Mukherjee, Section Editor)

Sexual Activity and Ischemic Heart Disease

Peripheral Vascular Disease (MH Shishehbor, Section Editor)

The Current State of Stem Cell Therapy for Peripheral Artery Disease

Echocardiography (RM Lang, Section Editor)

Procedural Guidance Using Advance Imaging Techniques for Percutaneous Edge-to-Edge Mitral Valve Repair

Neu im Fachgebiet Kardiologie

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Dihydropyridin-Kalziumantagonisten können auf die Nieren gehen

30.04.2024 Hypertonie Nachrichten

Im Vergleich zu anderen Blutdrucksenkern sind Kalziumantagonisten vom Diyhdropyridin-Typ mit einem erhöhten Risiko für eine Mikroalbuminurie und in Abwesenheit eines RAS-Blockers auch für ein terminales Nierenversagen verbunden.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise